{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-036162","form_type":"8-K","ticker":null,"cik":"0001923840","company_name":"Third Harmonic Bio, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.319023+00:00","generated_at":"2026-06-04T08:07:54.664503+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Third Harmonic Bio reports $269.1M cash, files IND for THB335, Q4 net loss narrows","bullets":["Cash and equivalents $269.1M as of Dec 31, 2023; expected to fund operations through at least 2026.","Net loss for Q4 2023 was $6.8M versus $11.5M in Q4 2022; full-year net loss $30.8M.","R&D expenses decreased to $5.9M in Q4 2023 from $9.3M year-over-year.","U.S. IND filed for THB335, a potential first-in-class oral KIT inhibitor for chronic spontaneous urticaria.","Phase 1 SAD/14-day MAD study in healthy volunteers anticipated to start in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-036162","json":"https://secwatch.observer/filing/0000950170-24-036162.json","markdown":"https://secwatch.observer/filing/0000950170-24-036162.md","text":"https://secwatch.observer/filing/0000950170-24-036162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1923840/000095017024036162/0000950170-24-036162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1923840/000095017024036162/thrd-20240326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:07:54.664503+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b4fe4c2a393d0800d4daf9cb36b9d3e109474cbe","claim":"Third Harmonic Bio, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the three months ended December 31, 2023 decreased to $6.8 million from a net loss of $11.5 million for the.","evidence_excerpt":"Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1923840/000095017024036162/0000950170-24-036162-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the three months ended December 31, 2023 decreased to $6.8 million from a net loss of $11.5 million for the"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}